University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Lee-may Chen, MD

Lee-may Chen, MD

Clinical Professor, Department of Obstetrics, Gynecology, and Reproductive Sciences, UCSF
John A. Kerner Distingished Professor in Gynecologic Oncology

Cancer Center Program Memberships

Cancer Genetics

Research Summary

Dr. Lee-may Chen is the Division Director and Program Director for the UCSF/KPSF Gynecologic Oncology Fellowship Program. She is deeply committed to education and improving the outcomes of gynecologic cancer care.

Since 2008, I have been the director of the UCSF Gynecologic Cancer Risk Program. With a strong collaboration between the Cancer Genetics and Prevention Program and the Department of Pathology, we have long been interested in identifying at-risk individuals and families for hereditary cancer syndromes. The decision for risk-reducing surgery is fraught with unknowns and anxiety for patients. By studying patient centered outcomes, we are better able to counsel women and personalize their decision making.

We are also working closely with the Medical Center on their Perioperative Pathway Program. By creating a surgical pathway for open & minimally invasive surgery cases, we have been able to reduce hospital length of stay and decrease costs without compromising patient satisfaction. Surgical pathways also proves a robust platform to teach quality improvement, and we have integrated medical students, residents, and fellows into various performance improvement projects (opiate disposal, bowel prep) along the patients’ journey.

Education

University of Michigan, Ann Arbor, MI, B.S., 1985-1989, Biomedical Sciences
University of Michigan Medical School, Ann Arbor, MI, M.D., 1988-1992, Chinese Studies, Medicine
University of Michigan Hospitals, Ann Arbor, MI, Residency, 1992-1996, Obstetrics & Gynecology
University of California, Los Angeles & Cedars-Sinai Medical Centers, Fellowship, 1996-1999, Gynecologic Oncology
University of California, San Francisco, San Francisco, CA, 2006-2007, Teaching Scholars Program
University of California, San Francisco, San Francisco, CA, 2010, Mentor Development Program


Professional Experience

  • 1999-2007
    Assistant Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2007-2011
    Associate Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco
  • 2011-present
    Clinical Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, & Reproductive Sciences, University of California, San Francisco

Honors & Awards

  • 1999
    ASCO/AACR Methods in Clinical Cancer Research Workshop
  • 2001
    Berlex Foundation, Junior Faculty Development Course
  • 2002
    ACOG/CREOG National Faculty Award
  • 2003-2005
    UCSF Department of Obstetrics, Gynecology, and Reproductive Sciences
  • 2007-2008
    Outstanding Resident Teaching Award
  • 2006
    Cancer Liason Physician Outstanding Performance Award
  • 2010
    Helen Diller Family Comprehensive Cancer Center Quality Award
  • 2010
    The Ernie H. Rosenbaum, MD Commitment to Patient Care Award
  • 2010-2015
    Edward C. Hill, MD, Endowed Chair

Selected Publications

  1. Sarin A, Lancaster E, Chen LL, Porten S, Chen LM, Lager J, Wick E. Using provider-focused education toolkits can aid enhanced recovery programs to further reduce patient exposure to opioids. Perioper Med (Lond). 2020; 9:21.
    View on PubMed
  2. Peters PN, Pierson WE, Chen LM, Westphalen AC, Chapman JS, Hsu IC. PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer. Abdom Radiol (NY). 2020 Jul 08.
    View on PubMed
  3. McNally L, Zhou Y, Robinson JF, Zhao G, Chen LM, Chen H, Kim MY, Kapidzic M, Gormley M, Hannibal R, Fisher SJ. Up-regulated cytotrophoblast DOCK4 contributes to over-invasion in placenta accreta spectrum. Proc Natl Acad Sci U S A. 2020 Jun 23.
    View on PubMed
  4. Pierson WE, Peters PN, Chang MT, Chen LM, Quigley DA, Ashworth A, Chapman JS. An integrated molecular profile of endometrioid ovarian cancer. Gynecol Oncol. 2020 Apr; 157(1):55-61.
    View on PubMed
  5. Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 508-514]. Gynecol Oncol. 2020 Mar; 156(3):748.
    View on PubMed
  6. O'Cearbhaill RE, Deng W, Chen LM, Lucci JA, Behbakht K, Spirtos NM, Muller CY, Benigno BB, Powell MA, Berry E, Tewari KS, Hanjani P, Lankes HA, Aghajanian C, Sabbatini PJ. A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):393-399.
    View on PubMed
  7. Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. Gynecol Oncol. 2019 12; 155(3):508-514.
    View on PubMed
  8. Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review. Fertil Steril. 2019 12; 112(6):1034-1042.
    View on PubMed
  9. Mazor M, Paul SM, Chesney MA, Chen LM, Smoot B, Topp K, Conley YP, Levine JD, Miaskowski C. Perceived stress is associated with a higher symptom burden in cancer survivors. Cancer. 2019 12 15; 125(24):4509-4515.
    View on PubMed
  10. Ahmad TR, Chen LM, Chapman JS, Chen LL. Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology. Gynecol Oncol. 2019 10; 155(1):93-97.
    View on PubMed
  11. Gupta S, Provenzale D, Llor X, Halverson AL, Grady W, Chung DC, Haraldsdottir S, Markowitz AJ, Slavin TP, Hampel H, Ness RM, Weiss JM, Ahnen DJ, Chen LM, Cooper G, Early DS, Giardiello FM, Hall MJ, Hamilton SR, Kanth P, Klapman JB, Lazenby AJ, Lynch PM, Mayer RJ, Mikkelson J, Peter S, Regenbogen SE, Dwyer MA, Ogba N. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Colorectal, Version 2.2019. J Natl Compr Canc Netw. 2019 09 01; 17(9):1032-1041.
    View on PubMed
  12. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, Berek JS, Chen LM, Cristea M, DeRosa M, ElNaggar AC, Gershenson DM, Gray HJ, Hakam A, Jain A, Johnston C, Leath CA, Liu J, Mahdi H, Matei D, McHale M, McLean K, O'Malley DM, Penson RT, Percac-Lima S, Ratner E, Remmenga SW, Sabbatini P, Werner TL, Zsiros E, Burns JL, Engh AM. NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019. J Natl Compr Canc Netw. 2019 08 01; 17(8):896-909.
    View on PubMed
  13. Jha P, Rabban J, Chen LM, Goldstein RB, Weinstein S, Morgan TA, Shum D, Hills N, Ohliger MA, Poder L. Placenta accreta spectrum: value of placental bulge as a sign of myometrial invasion on MR imaging. Abdom Radiol (NY). 2019 07; 44(7):2572-2581.
    View on PubMed
  14. Holschneider CH, Petereit DG, Chu C, Hsu IC, Ioffe YJ, Klopp AH, Pothuri B, Chen LM, Yashar C. Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS). Brachytherapy. 2019 Mar - Apr; 18(2):123-132.
    View on PubMed
  15. Holschneider CH, Petereit DG, Chu C, Hsu IC, Ioffe YJ, Klopp AH, Pothuri B, Chen LM, Yashar C. Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS). Gynecol Oncol. 2019 03; 152(3):540-547.
    View on PubMed
  16. Jha P, Behr S, Morgan T, Washburn E, Lucero J, Chen LM, Poder L. Imaging findings of concealed intra-amniotic hemorrhage in the setting of placenta previa and placenta accreta spectrum disorder. Emerg Radiol. 2018 Oct; 25(5):553-556.
    View on PubMed
  17. Manrriquez E, Chapman JS, Mak J, Blanco AM, Chen LM. Disparities in genetics assessment for women with ovarian cancer: Can we do better? Gynecol Oncol. 2018 04; 149(1):84-88.
    View on PubMed
  18. Liao CI, Chow S, Chen LM, Kapp DS, Mann A, Chan JK. Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US. Gynecol Oncol. 2018 05; 149(2):318-323.
    View on PubMed
  19. Swanson M, Ueda S, Chen LM, Huchko MJ, Nakisige C, Namugga J. Evidence-based improvisation: Facing the challenges of cervical cancer care in Uganda. Gynecol Oncol Rep. 2018 May; 24:30-35.
    View on PubMed
  20. Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol. 2017 11; 147(2):267-275.
    View on PubMed

Go to UCSF Profiles, powered by CTSI